These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 34714720

  • 1. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S, Nicolas JF, Szymanski H, Leroux-Roels I, Schaum T, Bonten M, Icardi G, Shrestha A, Tabar C, QHD00011 study team.
    Hum Vaccin Immunother; 2021 Dec 02; 17(12):5475-5486. PubMed ID: 34714720
    [Abstract] [Full Text] [Related]

  • 2. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L, Nakama T, Nagai H, Matsuoka O, Inoue S, Inoue T, Shrestha A, Pandey A, Chang LJ, De Bruijn I, QHD00010 Study Group.
    Vaccine; 2023 Apr 06; 41(15):2553-2561. PubMed ID: 36906404
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ, Meng Y, Janosczyk H, Landolfi V, Talbot HK, QHD00013 Study Group.
    Vaccine; 2019 Sep 16; 37(39):5825-5834. PubMed ID: 31431411
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L, Matsuoka O, Inoue S, Inoue T, Meng Y, Nakama T, Kato K, Pandey A, Chang LJ.
    Hum Vaccin Immunother; 2020 Apr 02; 16(4):858-866. PubMed ID: 31634025
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ, Anderson EJ, Jeanfreau R, He Y, Hicks B, Shrestha A, Pandey A, Landolfi V, DeBruijn I, QHD04 Study Group.
    Vaccine; 2021 Mar 12; 39(11):1572-1582. PubMed ID: 33610374
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.
    Vaccine; 2015 May 15; 33(21):2485-92. PubMed ID: 25843270
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
    Chu K, Xu K, Tang R, Tian X, Hu J, Yang T, Li C, Hu Y, Zeng G.
    Vaccine; 2020 Aug 18; 38(37):5940-5946. PubMed ID: 32732142
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB.
    Ann Pharmacother; 2021 Jan 18; 55(1):89-97. PubMed ID: 32578447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V, Cho I, Plested JS, Agrawal S, Fiske J, Cai R, Zhou H, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou B, Lewis M, Price-Abbott P, Patel N, Massare MJ, Smith G, Keech C, Fries L, Glenn GM.
    Lancet Infect Dis; 2022 Jan 18; 22(1):73-84. PubMed ID: 34563277
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS, Noh JY, Lee J, Choi JY, Lee JS, Kim MS, Kim HS, Bang J, Lavis N, Kim WJ.
    Hum Vaccin Immunother; 2018 Mar 04; 14(3):587-592. PubMed ID: 28933625
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
    Huang X, Fan T, Li L, Nian X, Zhang J, Gao X, Zhao W, Chen W, Zhang Z, Yao Z, Han X, Shi J, Wang Y, Bian H, Shi N, Li X, Duan K, Li G, Yang X.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2079924. PubMed ID: 35714276
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.